DXC TECHNOLOGY CO (DXC)       28.15  +0.72 (+2.62%)

28.15  +0.72 (+2.62%)

US23355L1061 - Common Stock - After market: 28.15 0 (0%)


Fundamental Rating

4

Taking everything into account, DXC scores 4 out of 10 in our fundamental rating. DXC was compared to 154 industry peers in the IT Services industry. DXC has a medium profitability rating, but doesn't score so well on its financial health evaluation. DXC is valued quite cheap, while showing a decent growth score. This is a good combination!




Profitability

Profitability Rating

4

The Piotroski-F score of DXC is 9.00. This is a very strong score and indicates great health and profitability for DXC.
DXC's Return On Equity of 16.40% is in line with the rest of the industry. The industry average Return On Equity is 15.58%.

DXC's Return On Assets of 4.27% is worse than the rest of the industry. The industry average Return On Assets is 5.75%.
DXC's Profit Margin of 4.93% is worse than the rest of the industry. The industry average Profit Margin is 8.50%.
VS Industry

ROA (4.27%) VS Industry: 36% outperformed.

0.04
1,363.02

ROE (16.4%) VS Industry: 52% outperformed.

0.31
157.67

Profit Margin (4.93%) VS Industry: 32% outperformed.

0.12
59.05

Valuation

Valuation Rating

7

The Price/Earnings Ratio is 8.63, which indicates a very decent valuation of DXC.
Compared to an average industry Price/Earning Ratio of 19.53, DXC is valued rather cheaply. On top of this DXC is cheaper than 91% of the companies listed in the same industry.
The Forward Price/Earnings Ratio of 6.04 indicates a rather cheap valuation of DXC.
Compared to an average industry price book ratio of 3.05, DXC is valued rather cheaply

When comparing the Enterprise Value to EBITDA ratio of DXC to the average industry ratio of 12.42, DXC is valued rather cheaply. DXC is also cheaper than 96% of the companies listed in the same industry.
When comparing the current price to the book value of DXC, we can conclude it is valued correctly. It is trading at 1.39 times its book value.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
VS Industry

Price/Earnings (8.63) VS Industry: 91% outperformed.

2,040.18
0.02

Price/Book (1.39) VS Industry: 74% outperformed.

96.88
0.09

Enterprise Value/ EBITDA (2.63) VS Industry: 96% outperformed.

724.49
1.71

Growth

Growth Rating

4

DXC is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 14.63% yearly.
The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
DXC shows quite a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 16.41% yearly.
The earnings per share for DXC have decreased by -1.51% in the last year.

Measured over the past 5 years, DXC shows a small growth in Earnings Per Share. The EPS has been growing by 2.40% on average per year.
DXC shows a decrease in Revenue. In the last year, the revenue decreased by -8.73%.
Based on estimates for the next 5 years, DXC will show a decrease in Revenue. The Revenue will decrease by -3.86% on average per year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS2.4% -25.29% -1.51% 1.63% 15.56% 14.63% N/A
Revenue16.41% -7.8% -8.73% -11.73% -6.34% -3.86% N/A

Health

Health Rating

3

The Piotroski-F score of DXC is 9.00. This is a very strong score and indicates great health and profitability for DXC.
DXC has a Current Ratio of 1.14. This is a normal value and indicates that DXC is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.14 indicates that DXC should not have too much problems paying its short term obligations.
When comparing the Current Ratio of DXC to the average industry Current Ratio of 1.46, DXC is less able to pay its short term obligations than its industry peers.

When comparing the Quick Ratio of DXC to the average industry Current Ratio of 1.44, DXC is less able to pay its short term obligations than its industry peers.
When comparing the Debt to Equity Ratio of DXC to the average industry Debt to Equity Ratio of 0.32, DXC required more debt to finance its operations than its industry peers.
Based on the Altman-Z score of 1.14, we must say that DXC is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 1.96, DXC is in worse financial health than its industry peers.
VS Industry

Debt/Equity (0.8) VS Industry: 27% outperformed.

48.59
0.00

Quick Ratio (1.14) VS Industry: 34% outperformed.

0.04
11.05

Current Ratio (1.14) VS Industry: 33% outperformed.

0.04
11.05

Altman-Z (1.14) VS Industry: 36% outperformed.

-270.35
24.56

Dividend

Dividend Rating

0

DXC does not give a dividend.

DXC TECHNOLOGY CO28.15

NYSE:DXC (2/7/2023, 7:04:00 PM)+0.72 (+2.62%)

After market: 28.15 0 (0%)

Chartmill FA Rating
GICS Sector Information Technology
GICS IndustryGroup Software & Services
GICS Industry IT Services
Earnings (Last) 02-01 2023-02-01/amc Earnings (Next) 05-23 2023-05-23/amc
Inst Owners 89.35% Inst Owner Change -1.35%
Ins Owners 0.71% Ins Owner Change -5.22%
Market Cap 6.41B Analysts 69.47
Price Target 34.52 (22.63%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP 0%
Div Incr Years 1 Div Non Decr Years 1
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) -3.98%
Min EPS beat(2) -9.44% Max EPS beat(2) 1.49%
EPS beat(4) 1 Avg EPS beat(4) -6.11%
Min EPS beat(4) -16.13% Max EPS beat(4) 1.49%
Revenue beat(2) N/A Avg Revenue beat(2) -0.98%
Min Revenue beat(2) -1.41% Max Revenue beat(2) -0.56%
Revenue beat(4) N/A Avg Revenue beat(4) -1.7%
Min Revenue beat(4) -3.68% Max Revenue beat(4) -0.56%
PT rev (1m) -0.94% PT rev (3m) -0.45%
EPS NQ rev (1m) N/A EPS NQ rev (3m) N/A
EPS NY rev (1m) 0% EPS NY rev (3m) -0.76%
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) 0% Revenue NY rev (3m) -0.73%

Valuation
Industry RankSector Rank
PE 8.63
Fwd PE 6.04
P/S 0.42
P/FCF 9.91
P/OCF 4.78
P/B 1.39
P/tB 5.48
EV/EBITDA 2.63
EPS(TTM) 3.26 EY 11.58%
EPS(NY) 4.66 Fwd EY 16.56%
FCF(TTM) 2.84 FCFY 10.09%
OCF(TTM) 5.89 OCFY 20.92%
SpS 67.51 BVpS 20.27
TBVpS 5.13 PEG (NY) 5.28
PEG (5Y) 3.6

Profitability
Industry RankSector Rank
ROA 4.27%
ROE 16.4%
ROIC 9.33%
ROICexc 11.45%
ROICexgc 17.49%
OM 9.41%
PM 4.93%
GM 21.63%
ROICexgc(3y) N/A ROICexcg growth 3Y -27.9%
ROICexcg growth 5Y 35.71% ROICexc(3y) N/A
ROICexc growth 3Y -0.76% ROICexc growth 5Y 59.47%
OM growth 3Y -8.59% OM growth 5Y 59.7%
PM growth 3Y -10.01% PM growth 5Y N/A
GM growth 3Y -7.67% GM growth 5Y -4.07%
F-Score 9 Asset Turnover 0.87

Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 7
Debt/EBITDA 1.46
Cap/Depr 42.09%
Profit Quality 85.47%
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z 1.14
F-Score 9 WACC 9.1%
ROIC/WACC 1.92 Cap/Depr(3y) 42.24%
Cap/Depr(5y) 42.33% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -1.51% EPS 3Y -25.29%
EPS 5Y 2.4% EPS growth Q2Q -15.73%
EPS Next Y 1.63% EPS Next 2Y 15.56%
EPS Next 3Y 14.63% EPS Next 5Y N/A
Revenue growth 1Y -8.73% Revenue growth 3Y -7.8%
Revenue growth 5Y 16.41% Revenue growth Q2Q -11.45%
Revenue Next Year -11.73% Revenue Next 2Y -6.34%
Revenue Next 3Y -3.86% Revenue Next 5Y N/A
EBIT growth 1Y 1202.7% EBIT growth 3Y -15.72%
EBIT growth 5Y 85.92% EBIT Next Year 64.51%
EBIT Next 3Y 21.34% EBIT Next 5Y N/A
FCF growth 1Y 13.71% FCF growth 3Y -1.47%
FCF growth 5Y 43.21% OCF growth 1Y -0.89%
OCF growth 3Y -4.5% OCF growth 5Y 20.2%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA